Document is current
Any future updates will be listed below
-
Authors
Park, Seong Yeon https://orcid.org/0000-0001-8762-7006
Levin, Myron J.
Canniff, Jennifer
Johnson, Michael
Schmid, D. Scott
Weinberg, Adriana https://orcid.org/0000-0001-6920-0623
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (63007497)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (1U01AI141919-01)
National Research Foundation of Korea (NRF-2017R1C1B2003336)
Dongguk University (Research fund of 2019)
- License Information
-
More Information
Article History
Received: 31 May 2022
Accepted: 6 October 2022
First Online: 25 October 2022
Competing interests
: A.W. receives grants from G.S.K. and Merck and personal fees from Merck and Seqirus. M.J.L. received research grants from G.S.K., Merck, Moderna, and Saol Therapeutics (moneys to University of Colorado School of Medicine) and personal fees for Advisory Boards for Merck, G.S.K., Pfizer, and Curevo). S.Y.P., J.C., M.J. and D.S.S. declare no competing interests.
